ArticleCurrent protocols2021
PharmGKB, an Integrated Resource of Pharmacogenomic Knowledge.
Article in Current protocols, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Clinical Pharmacogenetics Implementation Consortium's consensus-based framework for assigning allele function.American journal of human genetics · 2025Guideline
- Whole genome sequencing of 1427 Mexican individuals from the oriGen cohort.Nature communications · 2026Article
- Review
- Obstetric pharmacogenomics.Journal of basic and clinical physiology and pharmacology · 2026Review
- Using Artificial Intelligence to Identify Patterns and Predictors of Adverse Drug Reactions in Cardiovascular Patients: A Comprehensive Narrative Review.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Review
- Article
- Pharmacogenomics of antibacterial and antiviral therapies: Clinical actionability, evidence gaps, and future directions.Pharmacological reviews · 2026Review
- The potential of whole genome sequencing in pharmacogenetics: a retrospective health record study in rare disease patients.European journal of human genetics : EJHG · 2026Article
- Cardiovascular prescriber attitudes to pharmacogenomics: a survey by the ESC working group on cardiovascular pharmacotherapy.The pharmacogenomics journal · 2026Article
- ChatTogoVar: a TogoVar-based retrieval-augmented generation system for precise genomic variant interpretation.Human genome variation · 2026Article
- IMGT® at scale: FAIR, dynamic, and automated tools for immune locus analysis.Nucleic acids research · 2026Article
- The critical need to implement pharmacogenomics in public health services: Mexico in the global picture.Frontiers in public health · 2026Article
- Genetics to Improve Outcomes in Schizophrenia (GENios): A within-case molecular genetic study protocol.PloS one · 2026Article
- Systematic annotation and analysis of susceptibility genes associated with vaccine adverse events.BMC medical genomics · 2025Article
- Developmentally dynamic chromatin state at loci regulating organ crosstalk by remote sensing and signaling.Epigenetics & chromatin · 2025Article
- Empirical Drug Dosage Validates Pharmacogenomic Associations in All of Us.Clinical and translational science · 2025Article
- Genome-wide screening of pharmacogenomic biomarkers in jordanian patients with genetic disorders.The pharmacogenomics journal · 2025Article
- Genetic data normalization for genomic medicine: a Fast Healthcare Interoperability Resources Genomics reference implementation.Journal of the American Medical Informatics Association : JAMIA · 2025Article
- CASTER-DTA: Equivariant Graph Neural Networks for Predicting Drug-Target Affinity.bioRxiv : the preprint server for biology · 2025Article
- CASTER-DTA: equivariant graph neural networks for predicting drug-target affinity.Briefings in bioinformatics · 2025Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The Pharmacogenomics Knowledgebase (PharmGKB) is an integrated online knowledge resource for the understanding of how genetic variation contributes to variation in drug response. Our focus includes not only pharmacogenomic information useful for clinical implementation (e.g., drug dosing guidelines and annotated drug labels), but also information to catalyze scientific research and drug discovery (e.g., variant-drug annotations and drug-centered pathways). As of April 2021, the annotated content of PharmGKB spans 715 drugs, 1761 genes, 227 diseases, 165 clinical guidelines, and 784 drug labels. We have manually curated data from more than 9000 published papers to generate the content of PharmGKB. Recently, we have also implemented an automated natural language processing (NLP) tool to broaden our coverage of the pharmacogenomic literature. This article contains a basic protocol describing how to navigate the PharmGKB website to retrieve information on how genes and genetic variations affect drug efficacy and toxicity. It also includes a protocol on how to use PharmGKB to facilitate interpretation of findings for a pharmacogenomic variant genotype or metabolizer phenotype. PharmGKB is freely available at http://www.pharmgkb.org. © 2021 Wiley Periodicals LLC. Basic Protocol 1: Navigating the homepage of PharmGKB and searching by drug Basic Protocol 2: Using PharmGKB to facilitate interpretation of pharmacogenomic variant genotypes or metabolizer phenotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.